The UK and US have hammered out a key commercial pact that will preserve no duties on British medicine exports going into the US market.
Agreement Details of the Pact
As part of the deal, the UK has agreed to raise expenditure on pharmaceuticals through the NHS. This commitment secures that import taxes on these vital products will remain at nothing for a duration of three years.
This deal is in response to previous statements to significantly raise import taxes on branded drug products, with increases mentioned reaching double the cost.
"This deal with the Britain strengthens the global environment for new treatments and establishes long-overdue balance to U.S.–U.K. medicine commerce," a release noted.
Trade Impact
Medicines constitute one of the Britain's largest goods shipped to the US, which is easily the largest buyer for major companies like GSK and AstraZeneca.
Trade data show that in the 12 months to the end of September, the UK exported pharmaceutical products totaling £11.1bn to the US. This figure accounted for a significant portion of total UK exports in that span.
"This agreement safeguards employment, stimulates investment and sets the stage for the UK to emerge as a worldwide center for life sciences," a minister remarked.
Key UK Commitments
The pact includes several key commitments from the British government:
- Price Threshold Increase: The UK will lift the price threshold at which it considers new therapies to be unaffordable by a quarter.
- Higher Drug Budget: There is a goal to double overall health service expenditure on treatments from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Payback Limit: The sum manufacturers must return to the NHS to control costs will be capped at fifteen percent. Previously, repayments were more than twenty percent.
Recent Tensions
The deal takes place against a protracted tension between the pharmaceutical industry and the British authorities over spending levels and approval rates.
This friction were heightened by assertions that US customers were charged a premium for the same drugs than consumers in the Britain and the EU.
In recent months, several significant pharmaceutical investments in the UK have been halted or cancelled, while multi-billion-dollar funding commitments have been directed toward US facilities.
A senior figure stated that the NHS must invest a greater share on drugs, noting that its spending on drugs had shrunk as a percentage of its total funding over the past decade.
